IBD in children: Lessons for adults

被引：9

作者：

Haller C.A. ^{[1
]}

Markowitz J. ^{[1
]}

机构：

[1] Schneider Children's Hospital, New Hyde Park, NY 11040

来源：

Current Gastroenterology Reports | 2007年 / 9卷 / 6期

关键词：

Enteral Nutrition; Reach Trial;

D O I：

10.1007/s11894-007-0070-8

中图分类号：

学科分类号：

摘要：

When children develop inflammatory bowel disease (IBD), physicians and researchers are presented with a singular opportunity to understand the nature of these chronic, idiopathic illnesses in the earliest stages. Genetic susceptibility factors tend to be common, whereas complicating environmental factors such as cigarette smoking are generally not an issue. As opposed to the case in adult patients, Crohn's disease is usually diagnosed in children at an early, inflammatory phase of the disease. Pediatric ulcerative colitis tends to present with more severe and more extensive involvement than in adults. In both forms of IBD, the severity of disease activity often dictates the need for early aggressive nutritional, immunomodulatory, and biologic therapy. As a result the lessons learned from the evaluation and treatment of children with IBD are critically important to the clinician caring for adults with the same disorders. Copyright © 2007 by Current Medicine Group LLC.

引用

页码：528 / 532

页数：4

共 40 条

[11]

Dubinsky M., Lin-Chao L., Dutridge D., Et al., Serum immune responses predict rapid disease progression among children with Crohn's disease: Immune responses predict disease progression, Am J Gastroenterol, 101, pp. 360-367, (2006)

[12]

Amre D.K., Lu S.E., Seidman E.G., Et al., Utility of serological markers in predicting the early occurrence of complications and surgery in pediatric Crohn's disease patients, Am J Gastroenterol, 101, pp. 645-652, (2006)

[13]

Hyams J., Markowitz J., Lerer T., Et al., The natural history of corticosteroid therapy for ulcerative colitis in children, Clin Gastroenterol Hepatol, 4, pp. 1118-1123, (2006)

[14]

Faubion Jr W.A., Loftus Jr E.V., Harmsen W.S., Et al., The natural history of corticosteroid therapy for inflammatory bowel disease: A population-based study, Gastroenterology, 121, pp. 255-260, (2001)

[15]

Markowitz J., Grancher K., Kohn N., Et al., A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease, Gastroenterology, 119, pp. 895-902, (2000)

[16]

Markowitz J., Hyams J., Mack D., Et al., Corticosteroid therapy in the age of infliximab: Acute and 1-year outcomes in newly diagnosed children with Crohn's disease, Clin Gastroenterol Hepatol, 4, pp. 1124-1129, (2006)

[17]

Ballinger A.B., Azooz O., El-Haj T., Growth failure occurs through a decrease in insulin-like growth factor 1 which is independent of undernutrition in a rat model of colitis, Gut, 46, pp. 695-700, (2000)

[18]

Bannaerjee K., Camacho-Hubner C., Babinska K., Et al., Anti-inflammatory and growth-stimulating effects precede nutritional restitution during enteral feeding in Crohn disease, J Pediatr Gastroenterol Nutr, 38, pp. 270-275, (2004)

[19]

Johnson T., Macdonald S., Hill S.M., Et al., Treatment of active Crohn's disease in children using partial enteral nutrition with liquid formula: A randomized controlled trial, Gut, 55, pp. 356-361, (2006)

[20]

Griffiths A.M., Ohlsson A., Sherman P.M., Et al., Meta-analysis of enteral nutrition as the primary treatment of active Crohn's disease, Gastroenterology, 108, pp. 1056-1067, (1995)

← 1 2 3 4 →